Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients With Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis Publisher Pubmed



Shabaninejad H1 ; Asgharzadeh A2 ; Rezaei N3 ; Rezapoor A4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Health Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran
  2. 2. School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Research Center for Immunodeficiencies, Childrens Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran

Source: Expert Review of Clinical Immunology Published:2016


Abstract

Subcutaneous immunoglobulin (SCIG) is a new therapeutic procedure for patients with primary immunodeficiency (PI). This research is a systematic review of studies on the efficacy and safety of intravenous immunoglobulin (IVIG) and SCIG in adult patients with PI. This study includes a systematic review of cohorts and randomized clinical trials (24 articles) from 5 databases with no time limits. Random effects meta-analysis was performed for outcomes such as efficacy and safety. Standard mean difference (SMD) of serum immunoglobulin level was equal to 0.336 (P <0.01; 0.205-0.467) and the odds ratio (OR) of side effects was 0.497 (P=0.1; 0.180-1.371). The results indicate that SCIG leads to a higher level of immunoglobulin and a reduction in side effects but shows the same infection rate as IVIG. Our analysis shows that shifting from IVIG to SCIG therapy can have clinical benefits for PI patients. © 2016 Informa UK Limited.
Related Docs
View other Related Docs
1. Cost-Effectiveness Analysis of Subcutaneous Immunoglobulin Replacement Therapy in Iranian Patients With Primary Immunodeficiencies, Medical Journal of the Islamic Republic of Iran (2017)
2. Estimating the Cost of Immunoglobulin Replacement Therapy in Primary Immunodeficiency Patients, Iranian Journal of Pediatrics (2017)
3. The Use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases, Endocrine# Metabolic and Immune Disorders - Drug Targets (2016)
4. Managing Patients With Side Effects and Adverse Events to Immunoglobulin Therapy, Expert Review of Clinical Pharmacology (2016)
5. Economic Burden of Common Variable Immunodeficiency: Annual Cost of Disease, Expert Review of Clinical Immunology (2015)
6. Different Brands of Intravenous Immunoglobulin for Primary Immunodeficiencies: How to Choose the Best Option for the Patient?, Expert Review of Clinical Immunology (2015)
7. Agammaglobulinemia: Comorbidities and Long-Term Therapeutic Risks, Expert Opinion on Orphan Drugs (2017)
8. The Hyper Igm Syndromes: Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis and Management, Clinical Immunology (2019)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (8)
Zahra Pourpak (1)
Other Related Docs
9. A New Il-2Rg Gene Mutation in an X-Linked Scid Identified Through Trec/Krec Screening: A Case Report, Iranian Journal of Allergy# Asthma and Immunology (2015)
10. Primary Immunodeficiency Diseases in Iran: Past, Present and Future, Archives of Iranian Medicine (2021)
11. Adverse Reactions in a Large Cohort of Patients With Inborn Errors of Immunity Receiving Intravenous Immunoglobulin, Clinical Immunology (2021)